A New Insight Emerges in the Long COVID Puzzle
For many individuals recovering from SARS-CoV-2 infection, the journey is far from over. In Germany, as many as ten percent of those infected experience the debilitating effects of Long COVID. Symptoms such as extreme fatigue, cognitive difficulties, respiratory complications, and neurological issues can persist for months or even years. The experience of Long COVID varies significantly among individuals, making it a perplexing condition. "Long COVID is an incredibly intricate illness with various forms of expression," notes Prof. Yang Li, who oversees the "Computational Biology for Individualized Medicine" department and directs the Centre for Individualised Infection Medicine (CiiM). "The mechanisms of Long COVID are still largely a mystery. In many ways, we are staring at a puzzle with significant pieces missing."
To address this challenge, a research team led by Prof. Yang Li, alongside collaborators including Prof. Thomas Illig from Hannover Medical School (MHH) and Prof. Jie Sun from the University of Virginia, set out to uncover crucial elements that might illuminate the underlying causes of Long COVID. Their investigation focused on analyzing immune cells from patients diagnosed with Long COVID, utilizing samples sourced from MHH's biobank. "We employed a technique known as single-cell multiomics, which enables us to assess the molecular status within individual cells and understand their interrelationships," explains Dr. Saumya Kumar, a scientist at CiiM and the primary author of the study. The researchers also analyzed levels of pro-inflammatory substances called cytokines found in blood plasma. "What sets our study apart is our method of categorizing patient data based on the severity of their initial COVID-19 illness," Yang Li elaborates. "This approach has allowed us to identify distinct molecular differences in immune responses among patients, ultimately leading to the discovery of clear molecular features tied to the persistent symptoms of Long COVID."
How does the molecular landscape of immune cells evolve during Long COVID? Are there identifiable molecular markers linked to the severity of symptoms such as fatigue or respiratory distress? These were some of the pivotal questions explored in the team’s extensive data analysis. Notably, one significant finding emerged about a specific type of immune cell known as CD14+ monocytes. These white blood cells play a crucial role in the body's immune defense. "By utilizing single-cell analysis techniques, we were able to focus on these monocytes. We discovered that a particular molecular state, which we termed 'LC-Mo', was notably prevalent among Long COVID patients who had previously experienced mild to moderate COVID-19 infections," informs Saumya Kumar. "Moreover, the presence of LC-Mo was correlated with the severity of fatigue and respiratory issues, and it was linked to increased cytokine levels in the blood plasma, indicating ongoing inflammatory processes in the body."
The identification of LC-Mo represents a vital new piece of the Long COVID puzzle. "While its precise role in the progression of Long COVID remains to be fully defined, it opens up exciting avenues for future research, particularly in exploring genetic risk factors and personalized medical approaches," Yang Li adds. "Gaining a deeper understanding of how Long COVID develops may also shed light on the potential long-term effects of other infectious diseases."
This research received funding through an ERC Starting Grant (ModVaccine), along with support from the COVID-19 Research Network of Lower Saxony (COFONI) and the Lower Saxony Centre for AI & Causal Methods in Medicine (CAIMed), both funded by the Lower Saxony Ministry of Science and Culture (MWK), and the Federal Ministry of Research, Technology and Space (BMFTR).
Centre for Individualised Infection Medicine:
CiiM represents a collaborative effort between the Helmholtz Centre for Infection Research (HZI) and Hannover Medical School (MHH), marking the first research institute dedicated wholly to developing personalized treatments for infectious diseases. CiiM focuses on understanding individual patient characteristics and how they influence susceptibility to infections and the effectiveness of available therapies, striving for optimized care tailored to each person's unique needs. For more information, visit CiiM.
Helmholtz Centre for Infection Research:
At the Helmholtz Centre for Infection Research (HZI) located in Braunschweig and across its other facilities in Germany, scientists are engaged in investigating bacterial and viral infections and the body’s immune responses. They possess extensive expertise in researching natural compounds as a source for novel anti-infectives. As part of the Helmholtz Association and the German Center for Infection Research (DZIF), HZI conducts translational research aimed at paving the way for innovative treatments and vaccines against infectious diseases. To learn more, visit HZI.
*Public Release. This material originates from the organization or author(s) and may reflect time-sensitive information that has been edited for clarity, style, and length. Mirage.News does not hold institutional positions or opinions; all views expressed belong solely to the authors. View the full article here.
